Skip to content

CapEx at other companies

Eli Lilly logo
Eli LillyLLY
$2.33B+54.0%
Amgen logo
AmgenAMGN
$712M+73.2%
Immunome logo
ImmunomeIMNM
$3M-18.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0-100%
Nuvation Bio logo
Nuvation BioNUVB
$48K-33.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$23K-73.3%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's capex?
Bicara Therapeutics (BCAX) reported capex of $60K in Q1 2026.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.